The improvement of the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology is the goal of the new collaboration signed between Ferring Pharmaceuticals and Brasil-based Aché Laboratórios Farmacêuticos. According to the companies, potential benefits of the operation might include a reduction of adverse effects, increased patient adherence to treatment and more convenient dosing. From 2017, the joint R&D centre and programme Nanotechnology Innovation Laboratory Enterprise (NILE) will be housed at Aché’s R&D centre in São Paulo, Brazil, funded by Ferring and Aché and governed by a joint steering committee.
The exploitation of nanotechnology as a delivery system for future medicines through programmes designed to match each company’s therapeutic needs will be the core activity of the centre. Peptides and proteins in reproductive health, gastroenterology and urology will represent the main focus for Ferring, while the initiative will represent a strategic platform to accelerate new therapeutic entity developments for Aché.